Search

Your search keyword '"Borgen, Elin"' showing total 360 results
Start Over Author "Borgen, Elin"
360 results on '"Borgen, Elin"'

1. Deep learning for automated scoring of immunohistochemically stained tumour tissue sections – Validation across tumour types based on patient outcomes

Author

Bathen, Tone F., Borgen, Elin, Børresen-Dale, Anne-Lise, Engebråten, Olav, Fritzman, Britt, Hartman-Johnsen, Olaf Johan, Garred, Øystein, Geisler, Jürgen, Geitvik, Gry Aarum, Hofvind, Solveig, Kåresen, Rolf, Langerød, Anita, Lingjærde, Ole Christian, Mælandsmo, Gunhild M., Naume, Bjørn, Russnes, Hege G., Sahlberg, Kristine Kleivi, Sauer, Torill, Skjerven, Helle Kristine, Schlichting, Ellen, Sørlie, Therese, Kildal, Wanja, Cyll, Karolina, Kalsnes, Joakim, Islam, Rakibul, Julbø, Frida M., Pradhan, Manohar, Ersvær, Elin, Shepherd, Neil, Vlatkovic, Ljiljana, Tekpli, Xavier, Kristensen, Gunnar B., Askautrud, Hanne A., Hveem, Tarjei S., and Danielsen, Håvard E.

Published
2024
Full Text
View/download PDF

2. RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer

Author

Engebraaten, Olav, Yau, Christina, Berg, Kristian, Borgen, Elin, Garred, Øystein, Berstad, Maria EB, Fremstedal, Ane SV, DeMichele, Angela, Veer, Laura van ’t, Esserman, Laura, and Weyergang, Anette

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Clinical Trials and Supportive Activities, Cancer, Breast Cancer, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Ado-Trastuzumab Emtansine, Antibodies, Monoclonal, Humanized, Biomarkers, Tumor, Breast Neoplasms, Female, Humans, Trastuzumab, rab5 GTP-Binding Proteins
Abstract

HER2 is a predictive biomarker for HER2-targeted therapeutics. For antibody-drug conjugates (ADCs; e.g., trastuzumab emtansine (T-DM1)), HER2 is utilized as a transport gate for cytotoxic agents into the cell. ADC biomarkers may therefore be more complex, also reflecting the intracellular drug transport. Here we report on a positive correlation between the early endosome marker RAB5A and T-DM1 sensitivity in five HER2-positive cell lines. Correlation between RAB5A expression and T-DM1 sensitivity is confirmed in breast cancer patients treated with trastuzumab emtansine/pertuzumab in the I-SPY2 trial (NCT01042379), but not in the trastuzumab/paclitaxel control arm. The clinical correlation is further verified in patients from the KAMILLA trial (NCT01702571). In conclusion, our results suggest RAB5A as a predictive biomarker for T-DM1 response and outline proteins involved in endocytic trafficking as predictive biomarkers for ADCs.

Published
2021

3. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk

Author

Bathen, Tone F, Borgen, Elin, Fritzman, Britt, Garred, Øystein, Geitvik, Gry Aarum, Hofvind, Solveig, Langerød, Anita, Lingjærde, Ole Christian, Mælandsmo, Gunhild Mari, Russnes, Hege G, Skjerven, Helle Kristine, and Sørlie, Therese

Subjects
Genetics, Prevention, Breast Cancer, Aging, Clinical Research, Cancer, Aetiology, Detection, screening and diagnosis, 2.1 Biological and endogenous factors, 4.1 Discovery and preclinical testing of markers and technologies, Breast Neoplasms, Female, Genetic Predisposition to Disease, Genotyping Techniques, Germ-Line Mutation, Homeodomain Proteins, Humans, Middle Aged, Risk Factors, NBCS Collaborators, ABCTB Investigators
Abstract

In breast cancer, high levels of homeobox protein Hox-B13 (HOXB13) have been associated with disease progression of ER-positive breast cancer patients and resistance to tamoxifen treatment. Since HOXB13 p.G84E is a prostate cancer risk allele, we evaluated the association between HOXB13 germline mutations and breast cancer risk in a previous study consisting of 3,270 familial non-BRCA1/2 breast cancer cases and 2,327 controls from the Netherlands. Although both recurrent HOXB13 mutations p.G84E and p.R217C were not associated with breast cancer risk, the risk estimation for p.R217C was not very precise. To provide more conclusive evidence regarding the role of HOXB13 in breast cancer susceptibility, we here evaluated the association between HOXB13 mutations and increased breast cancer risk within 81 studies of the international Breast Cancer Association Consortium containing 68,521 invasive breast cancer patients and 54,865 controls. Both HOXB13 p.G84E and p.R217C did not associate with the development of breast cancer in European women, neither in the overall analysis (OR = 1.035, 95% CI = 0.859-1.246, P = 0.718 and OR = 0.798, 95% CI = 0.482-1.322, P = 0.381 respectively), nor in specific high-risk subgroups or breast cancer subtypes. Thus, although involved in breast cancer progression, HOXB13 is not a material breast cancer susceptibility gene.

Published
2020

4. Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis

Author

Hartkopf, Andreas D., Brucker, Sara Y., Taran, Florin-Andrei, Harbeck, Nadia, von Au, Alexandra, Naume, Bjørn, Pierga, Jean-Yves, Hoffmann, Oliver, Beckmann, Matthias W., Rydén, Lisa, Fehm, Tanja, Aft, Rebecca, Solà, Montserrat, Walter, Vincent, Rack, Brigitte, Schuetz, Florian, Borgen, Elin, Ta, Minh-Hanh, Bittner, Ann-Kathrin, Fasching, Peter A., Fernö, Mårten, Krawczyk, Natalia, Weilbaecher, Katherine, Margelí, Mireia, Hahn, Markus, Jueckstock, Julia, Domschke, Christoph, Bidard, Francois-Clement, Kasimir-Bauer, Sabine, Schoenfisch, Birgitt, Kurt, Ayse G., Wallwiener, Markus, Gebauer, Gerhard, Klein, Christoph A., Wallwiener, Diethelm, Janni, Wolfgang, and Pantel, Klaus

Published
2021
Full Text
View/download PDF

6. Comprehensive multi-omics analysis of breast cancer reveals distinct long-term prognostic subtypes.

Author

Sharma, Abhibhav, Debik, Julia, Naume, Bjørn, Ohnstad, Hege Oma, Oslo Breast Cancer Consortium (OSBREAC), Sahlber, Kristine Kleivi, Borgen, Elin, Børresen-Dale, Anne-Lise, Engebråten, Olav, Fritzman, Britt, Garred, Øystein, Geisler, Jürgen, Geitvik, Gry Aarum, Hofvind, Solveig, Kristensen, Vessela N, Kåresen, Rolf, Langerød, Anita, Lingjærde, Ole Christian, Mælandsmo, Gunhild Mari, and Russnes, Hege G

Published
2024
Full Text
View/download PDF

7. The prognostic significance of tumor cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients

Author

Molloy, Timothy J, Bosma, Astrid J, Baumbusch, Lars O, Synnestvedt, Marit, Borgen, Elin, Russnes, Hege, Schlichting, Ellen, van't Veer, Laura J, and Naume, Bjørn

Abstract

Abstract Introduction The detection of circulating tumour cells (CTCs) in the peripheral blood and disseminated tumour cells (DTCs) in the bone marrow are promising prognostic tools for risk stratification in early breast cancer. There is, however, a need for further validation of these techniques in larger patient cohorts with adequate follow-up periods. Methods We assayed CTCs and DTCs at primary surgery in 733 stage I or II breast cancer patients with a median follow-up time of 7.6 years. CTCs were detected in samples of peripheral blood mononuclear cells previously stored in liquid-nitrogen using a previously-developed multi-marker quantitative PCR (QPCR)-based assay. DTCs were detected in bone marrow samples by immunocytochemical analysis using anti-cytokeratin antibodies. Results CTCs were detected in 7.9% of patients, while DTCs were found in 11.7%. Both CTC and DTC positivity predicted poor metastasis-free survival (MFS) and breast cancer-specific survival (BCSS); MFS hazard ratio (HR) = 2.4 (P < 0.001)/1.9 (P = 0.006), and BCSS HR = 2.5 (P < 0.001)/2.3 (P = 0.01), for CTC/DTC status, respectively). Multivariate analyses demonstrated that CTC status was an independent prognostic variable for both MFS and BCSS. CTC status also identified a subset of patients with significantly poorer outcome among low-risk node negative patients that did not receive adjuvant systemic therapy (MFS HR 2.3 (P = 0.039), BCSS HR 2.9 (P = 0.017)). Using both tests provided increased prognostic information and indicated different relevance within biologically dissimilar breast cancer subtypes. Conclusions These results support the use of CTC analysis in early breast cancer to generate clinically useful prognostic information.

Published
2011

10. Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer

Author

Egeland, Eivind Valen, Boye, Kjetil, Park, Daehoon, Synnestvedt, Marit, Sauer, Torill, Naume, Bjørn, Borgen, Elin, Mælandsmo, Gunhild M., Sauer, Torill, Geisler, Jürgen, Hofvind, Solveig, Bathen, Tone F., Borgen, Elin, Børresen‐Dale, Anne‐Lise, Engebråten, Olav, Fodstad, Øystein, Garred, Øystein, Geitvik, Gry A., Kåresen, Rolf, Naume, Bjørn, Mælandsmo, Gunhild M., Russnes, Hege G., Schlichting, Ellen, Sørlie, Therese, Lingjærde, Ole C., Kristensen, Vessela N., Sahlberg, Kristine K., Skjerven, Helle K., Fritzman, Britt, and The Oslo Breast Cancer Consortium (OSBREAC)

Published
2017
Full Text
View/download PDF

11. Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer

Author

Sauer, Torill, Geisler, Jürgen, Hofvind, Solveig, Borgen, Elin, Børresen-Dale, Anne-Lise, Engebråten, Olav, Fodstad, Øystein, Garred, Øystein, Geitvik, Gry Aarum, Kåresen, Rolf, Naume, Bjørn, Mælandsmo, Gunhild Mari, Russnes, Hege G., Schlichting, Ellen, Sørlie, Therese, Lingjærde, Ole Christian, Kristensen, Vessela, Sahlberg, Kristine Kleivi, Skjerven, Helle Kristine, Fritzman, Britt, Lesurf, Robert, Aure, Miriam Ragle, Mørk, Hanne Håberg, Vitelli, Valeria, Lundgren, Steinar, Wärnberg, Fredrik, and Hallett, Michael

Published
2016
Full Text
View/download PDF

12. Breast cancer quantitative proteome and proteogenomic landscape

Author

Johansson, Henrik J., Socciarelli, Fabio, Vacanti, Nathaniel M., Haugen, Mads H., Zhu, Yafeng, Siavelis, Ioannis, Fernandez-Woodbridge, Alejandro, Aure, Miriam R., Sennblad, Bengt, Vesterlund, Mattias, Branca, Rui M., Orre, Lukas M., Huss, Mikael, Fredlund, Erik, Beraki, Elsa, Garred, Øystein, Boekel, Jorrit, Sauer, Torill, Zhao, Wei, Nord, Silje, Höglander, Elen K., Jans, Daniel C., Brismar, Hjalmar, Haukaas, Tonje H., Bathen, Tone F., Schlichting, Ellen, Naume, Bjørn, Consortia Oslo Breast Cancer Research Consortium (OSBREAC), Luders, Torben, Borgen, Elin, Kristensen, Vessela N., Russnes, Hege G., Lingjærde, Ole Christian, Mills, Gordon B., Sahlberg, Kristine K., Børresen-Dale, Anne-Lise, and Lehtiö, Janne

Published
2019
Full Text
View/download PDF

13. Supplementary Information from Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency

Author

Davies, Helen, primary, Morganella, Sandro, primary, Purdie, Colin A., primary, Jang, Se Jin, primary, Borgen, Elin, primary, Russnes, Hege, primary, Glodzik, Dominik, primary, Zou, Xueqing, primary, Viari, Alain, primary, Richardson, Andrea L., primary, Børresen-Dale, Anne-Lise, primary, Thompson, Alastair, primary, Eyfjord, Jorunn E., primary, Kong, Gu, primary, Stratton, Michael R., primary, and Nik-Zainal, Serena, primary

Published
2023
Full Text
View/download PDF

14. Data from Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data

Author

Lai, Xiaoran, primary, Geier, Oliver M., primary, Fleischer, Thomas, primary, Garred, Øystein, primary, Borgen, Elin, primary, Funke, Simon W., primary, Kumar, Surendra, primary, Rognes, Marie E., primary, Seierstad, Therese, primary, Børresen-Dale, Anne-Lise, primary, Kristensen, Vessela N., primary, Engebraaten, Olav, primary, Köhn-Luque, Alvaro, primary, and Frigessi, Arnoldo, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Table 2 from Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency

Author

Davies, Helen, primary, Morganella, Sandro, primary, Purdie, Colin A., primary, Jang, Se Jin, primary, Borgen, Elin, primary, Russnes, Hege, primary, Glodzik, Dominik, primary, Zou, Xueqing, primary, Viari, Alain, primary, Richardson, Andrea L., primary, Børresen-Dale, Anne-Lise, primary, Thompson, Alastair, primary, Eyfjord, Jorunn E., primary, Kong, Gu, primary, Stratton, Michael R., primary, and Nik-Zainal, Serena, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Table 4 from Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency

Author

Davies, Helen, primary, Morganella, Sandro, primary, Purdie, Colin A., primary, Jang, Se Jin, primary, Borgen, Elin, primary, Russnes, Hege, primary, Glodzik, Dominik, primary, Zou, Xueqing, primary, Viari, Alain, primary, Richardson, Andrea L., primary, Børresen-Dale, Anne-Lise, primary, Thompson, Alastair, primary, Eyfjord, Jorunn E., primary, Kong, Gu, primary, Stratton, Michael R., primary, and Nik-Zainal, Serena, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Text from Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data

Author

Lai, Xiaoran, primary, Geier, Oliver M., primary, Fleischer, Thomas, primary, Garred, Øystein, primary, Borgen, Elin, primary, Funke, Simon W., primary, Kumar, Surendra, primary, Rognes, Marie E., primary, Seierstad, Therese, primary, Børresen-Dale, Anne-Lise, primary, Kristensen, Vessela N., primary, Engebraaten, Olav, primary, Köhn-Luque, Alvaro, primary, and Frigessi, Arnoldo, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Tables from The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer

Author

Silwal-Pandit, Laxmi, primary, Nord, Silje, primary, von der Lippe Gythfeldt, Hedda, primary, Møller, Elen K., primary, Fleischer, Thomas, primary, Rødland, Einar, primary, Krohn, Marit, primary, Borgen, Elin, primary, Garred, Øystein, primary, Olsen, Tone, primary, Vu, Phuong, primary, Skjerven, Helle, primary, Fangberget, Anne, primary, Holmen, Marit M., primary, Schlitchting, Ellen, primary, Wille, Elisabeth, primary, Nordberg Stokke, Mette, primary, Moen Vollan, Hans Kristian, primary, Kristensen, Vessela, primary, Langerød, Anita, primary, Lundgren, Steinar, primary, Wist, Erik, primary, Naume, Bjørn, primary, Lingjærde, Ole Christian, primary, Børresen-Dale, Anne-Lise, primary, and Engebraaten, Olav, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Table 3 from Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency

Author

Davies, Helen, primary, Morganella, Sandro, primary, Purdie, Colin A., primary, Jang, Se Jin, primary, Borgen, Elin, primary, Russnes, Hege, primary, Glodzik, Dominik, primary, Zou, Xueqing, primary, Viari, Alain, primary, Richardson, Andrea L., primary, Børresen-Dale, Anne-Lise, primary, Thompson, Alastair, primary, Eyfjord, Jorunn E., primary, Kong, Gu, primary, Stratton, Michael R., primary, and Nik-Zainal, Serena, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Table S1 from Persistence of Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients Predicts Increased Risk for Relapse—A European Pooled Analysis

Author

Janni, Wolfgang, primary, Vogl, Florian D., primary, Wiedswang, Gro, primary, Synnestvedt, Marit, primary, Fehm, Tanja, primary, Jückstock, Julia, primary, Borgen, Elin, primary, Rack, Brigitte, primary, Braun, Stephan, primary, Sommer, Harald, primary, Solomayer, Erich, primary, Pantel, Klaus, primary, Nesland, Jahn, primary, Friese, Klaus, primary, and Naume, Bjørn, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Table 1 from Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency

Author

Davies, Helen, primary, Morganella, Sandro, primary, Purdie, Colin A., primary, Jang, Se Jin, primary, Borgen, Elin, primary, Russnes, Hege, primary, Glodzik, Dominik, primary, Zou, Xueqing, primary, Viari, Alain, primary, Richardson, Andrea L., primary, Børresen-Dale, Anne-Lise, primary, Thompson, Alastair, primary, Eyfjord, Jorunn E., primary, Kong, Gu, primary, Stratton, Michael R., primary, and Nik-Zainal, Serena, primary

Published
2023
Full Text
View/download PDF

23. Abstract PD11-11: PD11-11 Results from ALICE – Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple Negative Breast Cancer, a Randomized Phase IIb Trial

Author

Kyte, Jon Amund, primary, Røssevold, Andreas H., additional, Andresen, Nikolai K., additional, Bjerre, Christina Annette, additional, Gilje, Bjørnar, additional, Jakobsen, Erik Hugger, additional, Raj, Sunil Xavier, additional, Falk, Ragnhild Sørum, additional, Borgen, Elin, additional, Jahr, Thea, additional, Garred, Øystein, additional, Lømo, Jon, additional, Mathiesen, Randi Margit, additional, and Naume, Bjørn, additional

Published
2023
Full Text
View/download PDF

27. Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations

Author

Höglander, Elen Kristine, Nord, Silje, Wedge, David C., Lingjærde, Ole Christian, Silwal-Pandit, Laxmi, Gythfeldt, Hedda vdL, Vollan, Hans Kristian Moen, Fleischer, Thomas, Krohn, Marit, Schlitchting, Ellen, Borgen, Elin, Garred, Øystein, Holmen, Marit M., Wist, Erik, Naume, Bjørn, Van Loo, Peter, Børresen-Dale, Anne-Lise, Engebraaten, Olav, and Kristensen, Vessela

Published
2018
Full Text
View/download PDF

29. LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer

Author

Sas‐Chen, Aldema, Aure, Miriam R, Leibovich, Limor, Carvalho, Silvia, Enuka, Yehoshua, Körner, Cindy, Polycarpou‐Schwarz, Maria, Lavi, Sara, Nevo, Nava, Kuznetsov, Yuri, Yuan, Justin, Azuaje, Francisco, Ulitsky, Igor, Diederichs, Sven, Wiemann, Stefan, Yakhini, Zohar, Kristensen, Vessela N, Børresen‐Dale, Anne‐Lise, Yarden, Yosef, Sauer, Torill, Geisler, Jürgen, Hofvind, Solveig, Bathen, Tone F, Borgen, Elin, Engebråten, Olav, Fodstad, Øystein, Garred, Øystein, Geitvik, Gry Aarum, Kåresen, Rolf, Naume, Bjørn, Mælandsmo, Gunhild Mari, Russnes, Hege G, Schlichting, Ellen, Sørlie, Therese, Lingjærde, Ole Christian, Sahlberg, Kristine Kleivi, Skjerven, Helle Kristine, and Fritzman, Britt

Published
2016
Full Text
View/download PDF

31. Sample Preparation Approach Influences PAM50 Risk of Recurrence Score in Early Breast Cancer

Author

Lien, Tonje, primary, Ohnstad, Hege, additional, Lingjærde, Ole, additional, Vallon-Christersson, Johan, additional, Aaserud, Marit, additional, Sveli, My, additional, Borg, Åke, additional, OSBREAC, on, additional, Garred, Øystein, additional, Borgen, Elin, additional, Naume, Bjørn, additional, Russnes, Hege, additional, and Sørlie, Therese, additional

Published
2021
Full Text
View/download PDF

35. Subtype and cell type specific expression of lncRNAs provide insight into breast cancer.

Author

Bjørklund, Sunniva Stordal, Aure, Miriam Ragle, Häkkinen, Jari, Vallon-Christersson, Johan, Kumar, Surendra, Evensen, Katrine Bull, Fleischer, Thomas, Tost, Jörg, OSBREAC, Bathen, Tone F., Borgen, Elin, Børresen-Dale, Anne-Lise, Engebråten, Olav, Fritzman, Britt, Hartmann-Johnsen, Olaf Johan, Garred, Øystein, Geisler, Jürgen, Geitvik, Gry Aarum, Hofvind, Solveig, and Kåresen, Rolf

Subjects
BREAST cancer, LINCRNA, CARCINOGENESIS, REGULATOR genes, GENETIC transcription regulation, CANCER cells
Abstract

Long non-coding RNAs (lncRNAs) are involved in breast cancer pathogenesis through chromatin remodeling, transcriptional and post-transcriptional gene regulation. We report robust associations between lncRNA expression and breast cancer clinicopathological features in two population-based cohorts: SCAN-B and TCGA. Using co-expression analysis of lncRNAs with protein coding genes, we discovered three distinct clusters of lncRNAs. In silico cell type deconvolution coupled with single-cell RNA-seq analyses revealed that these three clusters were driven by cell type specific expression of lncRNAs. In one cluster lncRNAs were expressed by cancer cells and were mostly associated with the estrogen signaling pathways. In the two other clusters, lncRNAs were expressed either by immune cells or fibroblasts of the tumor microenvironment. To further investigate the cis-regulatory regions driving lncRNA expression in breast cancer, we identified subtype-specific transcription factor (TF) occupancy at lncRNA promoters. We also integrated lncRNA expression with DNA methylation data to identify long-range regulatory regions for lncRNA which were validated using ChiA-Pet-Pol2 loops. lncRNAs play an important role in shaping the gene regulatory landscape in breast cancer. We provide a detailed subtype and cell type-specific expression of lncRNA, which improves the understanding of underlying transcriptional regulation in breast cancer. Long non-coding RNAs (lncRNAs) have been shown to be involved in breast cancer pathogenesis through regulation of multiple steps of gene expression. lncRNA expression patterns are also associated with breast cancer clinicopathological features in large population-based cohorts. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

36. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk

Author

Liu, Jingjing, Prager - van der Smissen, Wendy J. C., Collée, J. Margriet, Bolla, Manjeet K., Wang, Qin, Michailidou, Kyriaki, Dennis, Joe, Ahearn, Thomas U., Aittomäki, Kristiina, Ambrosone, Christine B., Andrulis, Irene L., Anton-Culver, Hoda, Antonenkova, Natalia N., Arndt, Volker, Arnold, Norbert, Aronson, Kristan J., Augustinsson, Annelie, Auvinen, Päivi, Becher, Heiko, Beckmann, Matthias W., Behrens, Sabine, Bermisheva, Marina, Bernstein, Leslie, Bogdanova, Natalia V., Bogdanova-Markov, Nadja, Bojesen, Stig E., Brauch, Hiltrud, Brenner, Hermann, Briceno, Ignacio, Brucker, Sara Y., Brüning, Thomas, Burwinkel, Barbara, Cai, Qiuyin, Cai, Hui, Campa, Daniele, Canzian, Federico, Castelao, Jose E., Chang-Claude, Jenny, Chanock, Stephen J., Choi, Ji-Yeob, Christiaens, Melissa, Clarke, Christine L., Couch, Fergus J., Czene, Kamila, Daly, Mary B., Devilee, Peter, dos-Santos-Silva, Isabel, Dwek, Miriam, Eccles, Diana M., Eliassen, A. Heather, Fasching, Peter A., Figueroa, Jonine, Flyger, Henrik, Fritschi, Lin, Gago-Dominguez, Manuela, Gapstur, Susan M., García-Closas, Montserrat, García-Sáenz, José A., Gaudet, Mia M., Giles, Graham G., Goldberg, Mark S., Goldgar, David E., Guénel, Pascal, Haiman, Christopher A., Håkansson, Niclas, Hall, Per, Harrington, Patricia A., Hart, Steven N., Hartman, Mikael, Hillemanns, Peter, Hopper, John L., Hou, Ming-Feng, Hunter, David J., Huo, Dezheng, Ito, Hidemi, Iwasaki, Motoki, Jakimovska, Milena, Jakubowska, Anna, John, Esther M., Kaaks, Rudolf, Kang, Daehee, Keeman, Renske, Khusnutdinova, Elza, Kim, Sung-Won, Kraft, Peter, Kristensen, Vessela N., Kurian, Allison W., Le Marchand, Loic, Li, Jingmei, Lindblom, Annika, Lophatananon, Artitaya, Luben, Robert N., Lubiński, Jan, Mannermaa, Arto, Manoochehri, Mehdi, Manoukian, Siranoush, Margolin, Sara, Mariapun, Shivaani, Matsuo, Keitaro, Maurer, Tabea, Mavroudis, Dimitrios, Meindl, Alfons, Menon, Usha, Milne, Roger L., Muir, Kenneth, Mulligan, Anna Marie, Neuhausen, Susan L., Nevanlinna, Heli, Offit, Kenneth, Olopade, Olufunmilayo I., Olson, Janet E., Olsson, Håkan, Orr, Nick, Park, Sue K., Peterlongo, Paolo, Peto, Julian, Plaseska-Karanfilska, Dijana, Presneau, Nadege, Rack, Brigitte, Rau-Murthy, Rohini, Rennert, Gad, Rennert, Hedy S., Rhenius, Valerie, Romero, Atocha, Ruebner, Matthias, Saloustros, Emmanouil, Schmutzler, Rita K., Schneeweiss, Andreas, Scott, Christopher, Shah, Mitul, Shen, Chen-Yang, Shu, Xiao-Ou, Simard, Jacques, Sohn, Christof, Southey, Melissa C., Spinelli, John J., Tamimi, Rulla M., Tapper, William J., Teo, Soo H., Terry, Mary Beth, Torres, Diana, Truong, Thérèse, Untch, Michael, Vachon, Celine M., van Asperen, Christi J., Wolk, Alicja, Yamaji, Taiki, Zheng, Wei, Ziogas, Argyrios, Ziv, Elad, Torres-Mejía, Gabriela, Dörk, Thilo, Swerdlow, Anthony J., Hamann, Ute, Schmidt, Marjanka K., Dunning, Alison M., Pharoah, Paul D. P., Easton, Douglas F., Hooning, Maartje J., Martens, John W. M., Hollestelle, Antoinette, Sahlberg, Kristine K., Børresen-Dale, Anne-Lise, Ottestad, Lars, Kåresen, Rolf, Schlichting, Ellen, Holmen, Marit Muri, Sauer, Toril, Haakensen, Vilde, Engebråten, Olav, Naume, Bjørn, Fosså, Alexander, Kiserud, Cecile E., Reinertsen, Kristin V., Helland, Åslaug, Riis, Margit, Geisler, Jürgen, Alnæs, Grethe I. Grenaker, Bathen, Tone F., Borgen, Elin, Fritzman, Britt, Garred, Øystein, Geitvik, Gry Aarum, Hofvind, Solveig, Langerød, Anita, Lingjærde, Ole Christian, Mælandsmo, Gunhild Mari, Russnes, Hege G, Skjerven, Helle Kristine, Sørlie, Therese, Clarke, Christine, Marsh, Deborah, Scott, Rodney, Baxter, Robert, Yip, Desmond, Carpenter, Jane, Davis, Alison, Pathmanathan, Nirmala, Simpson, Peter, Graham, Dinny, Sachchithananthan, Mythily, and Apollo - University of Cambridge Repository

Subjects
631/67, 631/208, article, skin and connective tissue diseases, 692/499, 692/4028
Abstract

In breast cancer, high levels of homeobox protein Hox-B13 (HOXB13) have been associated with disease progression of ER-positive breast cancer patients and resistance to tamoxifen treatment. Since HOXB13 p.G84E is a prostate cancer risk allele, we evaluated the association between HOXB13 germline mutations and breast cancer risk in a previous study consisting of 3,270 familial non-BRCA1/2 breast cancer cases and 2,327 controls from the Netherlands. Although both recurrent HOXB13 mutations p.G84E and p.R217C were not associated with breast cancer risk, the risk estimation for p.R217C was not very precise. To provide more conclusive evidence regarding the role of HOXB13 in breast cancer susceptibility, we here evaluated the association between HOXB13 mutations and increased breast cancer risk within 81 studies of the international Breast Cancer Association Consortium containing 68,521 invasive breast cancer patients and 54,865 controls. Both HOXB13 p.G84E and p.R217C did not associate with the development of breast cancer in European women, neither in the overall analysis (OR = 1.035, 95% CI = 0.859–1.246, P = 0.718 and OR = 0.798, 95% CI = 0.482–1.322, P = 0.381 respectively), nor in specific high-risk subgroups or breast cancer subtypes. Thus, although involved in breast cancer progression, HOXB13 is not a material breast cancer susceptibility gene.

Published
2020

37. Additional file 1 of Cytokeratin-positive cells in the bone marrow from patients with pancreatic, periampullary malignancy and benign pancreatic disease show no prognostic information

Author

Hugenschmidt, Harald, Labori, Knut Jørgen, Brunborg, Cathrine, Verbeke, Caroline Sophie, Seeberg, Lars Thomas, Schirmer, Cecilie Bendigtsen, Renolen, Anne, Borgen, Elin, Naume, Bjørn, and Wiedswang, Gro

Abstract

Additional file 1 Figure S1: Overall survival sub-grouped by CTC status in resected and advanced cancers according to non-malignant ICC-status in bone marrow. Legend: Overall survival dependent on CTC-status for resected and advanced cancer patients with (pos.) or without (neg.) ICC-positive cells. P values were computed by log-rank test assuming p

Published
2020
Full Text
View/download PDF

38. Additional file 2 of Cytokeratin-positive cells in the bone marrow from patients with pancreatic, periampullary malignancy and benign pancreatic disease show no prognostic information

Author

Hugenschmidt, Harald, Labori, Knut Jørgen, Brunborg, Cathrine, Verbeke, Caroline Sophie, Seeberg, Lars Thomas, Schirmer, Cecilie Bendigtsen, Renolen, Anne, Borgen, Elin, Naume, Bjørn, and Wiedswang, Gro

Subjects
mental disorders, psychological phenomena and processes
Abstract

Additional file 2 Table S1: Clinical parameters of all ICC-positive patients

Published
2020
Full Text
View/download PDF

44. Low Z‐4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen

Author

Helland, Thomas, primary, Naume, Bjørn, additional, Hustad, Steinar, additional, Bifulco, Ersilia, additional, Kvaløy, Jan Terje, additional, Sætersdal, Anna Barbro, additional, Synnestvedt, Marit, additional, Lende, Tone Hoel, additional, Gilje, Bjørnar, additional, Mjaaland, Ingvil, additional, Weyde, Kjetil, additional, Blix, Egil Støre, additional, Wiedswang, Gro, additional, Borgen, Elin, additional, Hertz, Daniel Louis, additional, Janssen, Emiel Adrianus Maria, additional, Mellgren, Gunnar, additional, and Søiland, Håvard, additional

Published
2020
Full Text
View/download PDF

45. Cytokeratin-positive cells in the bone marrow from patients with pancreatic, periampullary malignancy and benign pancreatic disease show no prognostic information

Author

Hugenschmidt, Harald, primary, Labori, Knut Jørgen, additional, Brunborg, Cathrine, additional, Verbeke, Caroline Sophie, additional, Seeberg, Lars Thomas, additional, Schirmer, Cecilie Bendigtsen, additional, Renolen, Anne, additional, Borgen, Elin, additional, Naume, Bjørn, additional, and Wiedswang, Gro, additional

Published
2020
Full Text
View/download PDF

46. Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment ofER‐positive breast cancer

Author

Lippe Gythfeldt, Hedda, primary, Lien, Tonje, additional, Tekpli, Xavier, additional, Silwal‐Pandit, Laxmi, additional, Borgen, Elin, additional, Garred, Øystein, additional, Skjerven, Helle, additional, Schlichting, Ellen, additional, Lundgren, Steinar, additional, Wist, Erik, additional, Naume, Bjørn, additional, Kristensen, Vessela, additional, Børresen‐Dale, Anne‐Lise, additional, Lingjærde, Ole Christian, additional, and Engebraaten, Olav, additional

Published
2020
Full Text
View/download PDF

47. Circulating Tumor Cells are an Independent Predictor of Shorter Survival in Patients Undergoing Resection for Pancreatic and Periampullary Adenocarcinoma

Author

Hugenschmidt, Harald, primary, Labori, Knut Jørgen, additional, Brunborg, Cathrine, additional, Verbeke, Caroline Sophie, additional, Seeberg, Lars Thomas, additional, Schirmer, Cecilie Bendigtsen, additional, Renolen, Anne, additional, Borgen, Elin Faye, additional, Naume, Bjørn, additional, and Wiedswang, Gro, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results